/NBTX
NBTX Stock - Nanobiotix S.A.
Healthcare|BiotechnologyNASDAQ
$22.13+0.14%
+$0.03 (+0.14%) • Dec 19
81
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.85
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).85
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+17.5%upside
Target: $26.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NBTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$21.91 – $22.35
TARGET (TP)$26.00
STOP LOSS$20.36
RISK/REWARD1:2.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.48
52W High$30.35
52W Low$2.82
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $-11,609,000 | $36.21M | $4.78M | $2.65M | $50,000 |
| Gross Profit | $-11,609,000 | $36.21M | $3.79M | $2.65M | $50,000 |
| Gross Margin | 100.0% | 100.0% | 79.4% | 100.0% | 100.0% |
| Operating Income | $-68,392,000 | $-26,779,000 | $-46,702,000 | $-52,579,000 | $-36,428,000 |
| Net Income | $-68,132,000 | $-39,700,000 | $-57,043,000 | $-47,004,000 | $-33,623,000 |
| Net Margin | 586.9% | -109.6% | -1194.4% | -1775.7% | -67246.0% |
| EPS | $-1.44 | $-1.08 | $-1.64 | $-1.35 | $-1.38 |
Company Overview
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$12
Average Target
↓ 48.0% Downside
Now
$11
Low
$12
Average
$12
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 28th 2024 | Guggenheim | Initiation | Buy | $12 |
| December 8th 2023 | Leerink Partners | Initiation | Outperform | $11 |
Earnings History & Surprises
NBTXBeat Rate
67%
Last 9 quarters
Avg Surprise
+2.4%
EPS vs Estimate
Beats / Misses
6/3
Last 12 quarters
Latest EPS
$-0.13
Q3 2025
EPS Surprise History
Q1 22
+48.6%
$-0.54vs$-1.05
Q4 22
No data
Q1 23
No data
Q4 23
-47.6%
$-0.87vs$-0.59
Q2 24
+60.4%
$-0.33vs$-0.83
Q4 24
+2.5%
$-0.50vs$-0.51
Q2 25
-63.5%
$-1.01vs$-0.62
Q3 25
+45.9%
$-0.13vs$-0.25
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 19, 2026 | — | — | — | — |
Q3 2025 | Sep 30, 2025 | $-0.25 | $-0.13 | +45.9% | ✓ BEAT |
Q2 2025 | Apr 2, 2025 | $-0.62 | $-1.01 | -63.5% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.51 | $-0.50 | +2.5% | ✓ BEAT |
Q2 2024 | Apr 24, 2024 | $-0.83 | $-0.33 | +60.4% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.59 | $-0.87 | -47.6% | ✗ MISS |
Q1 2023 | Mar 28, 2023 | — | $-0.95 | — | — |
Q4 2022 | Nov 9, 2022 | — | $-0.79 | — | — |
Q1 2022 | Mar 30, 2022 | $-1.05 | $-0.54 | +48.6% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-0.60 | $-1.04 | -73.8% | ✗ MISS |
Q2 2021 | May 5, 2021 | $-1.01 | $-0.57 | +43.1% | ✓ BEAT |
Q4 2020 | Oct 23, 2020 | $-1.09 | $-1.02 | +5.9% | ✓ BEAT |
Q2 2020 | Apr 30, 2020 | — | $-1.37 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-1.30 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-1.08 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.75 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.86 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.87 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.79 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.76 | — | — |
Latest News
Nanobiotix Added To CAC Mid 60 And SBF 120 Indices, Boosting Visibility In European Equity Markets
📈 PositiveBenzinga•Dec 15, 2025, 07:56 AM
Nanobiotix Reports €20.4M In Cash And Cash Equivalents As Of Sept. 30
➖ NeutralBenzinga•Nov 24, 2025, 09:16 PM
Nanobiotix shares are trading higher after the company announced it entered into a $71 million royalty-based financing agreement with HealthCare Royalty.
📈 PositiveBenzinga•Oct 31, 2025, 01:22 PM•Also:
Nanobiotix And HealthCare Royalty Ink 71M Non-Dilutive Financing Agreement To Support JNJ-1900 (NBTXR3) Development And Long-Term Growth
📈 PositiveBenzinga•Oct 31, 2025, 07:18 AM•Also: ,
Nanobiotix Confirms Transfer Of NANORAY-312 Phase 3 Sponsorship And Operational Control To J&J With Interim Data Expected In 1H2027
📈 PositiveBenzinga•Oct 24, 2025, 06:32 AM•Also:
Nanobiotix gains after early-stage trial data for J&J-partnered cancer drug
📈 PositiveSeeking Alpha•Oct 2, 2025, 03:07 PM•Also:
NANOBIOTIX Announces First Data From Cohorts 1 And 2 Of Dose Escalation Part Of Phase 1 Study Evaluating JNJ-1900 For EADC Patients
➖ NeutralBenzinga•Oct 1, 2025, 08:18 PM•Also:
Nanobiotix H1 EPS $(0.12) Up From $(0.50) YoY, Sales $30.202M Up From $10.001M YoY
📈 PositiveBenzinga•Sep 30, 2025, 08:36 PM
Nanobiotix shares are trading higher after the company announced updated data from cohorts 1 and 2 of Study 1100.
📈 PositiveBenzinga•Sep 30, 2025, 12:54 PM
Reported Earlier, Nanobiotix Reports Updated Phase 1 Data Showing JNJ-1900 (NBTXR3) Plus Anti-PD-1 Achieves 37% ORR And 63% DCR In Naïve R/M-HNSCC Patients
📈 PositiveBenzinga•Sep 30, 2025, 06:40 AM•Also:
Nanobiotix shares are trading higher after the company announced new results focused on patients with primary cutaneous melanoma from the ongoing Phase 1 Study 1100 evaluating JNJ-1900 in combination with immune checkpoint inhibitors for patients with advanced cancers.
📈 PositiveBenzinga•Sep 18, 2025, 01:16 PM•Also:
Nanobiotix soars on positive phase 1 results for JNJ-1900 in melanoma
📈 PositiveSeeking Alpha•Sep 18, 2025, 08:01 AM•Also:
Nanobiotix Presents Data Showing A Favorable Safety Profile And Early Efficacy Signals In A Heavily Pre-Treated Population Whose Cancer Progressed After Multiple Prior Lines Of Therapy Including Anti-PD-1; Reports 47.4% ORR And 14.6-Month mOS In Phase 1 Study Of JNJ-1900
📈 PositiveBenzinga•Sep 17, 2025, 08:19 PM•Also:
Frequently Asked Questions about NBTX
What is NBTX's current stock price?
Nanobiotix S.A. (NBTX) is currently trading at $22.13 per share. The stock has moved +0.14% today.
What is the analyst price target for NBTX?
The average analyst price target for NBTX is $26.00, based on 1 analyst.
What sector is Nanobiotix S.A. in?
Nanobiotix S.A. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NBTX's market cap?
Nanobiotix S.A. has a market capitalization of $1.05 billion, making it a small-cap company.
Does NBTX pay dividends?
No, Nanobiotix S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABUS
Arbutus Biopharma Corporation
$4.43
Mkt Cap: $0.9B
EYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
GHRS
GH Research PLC
$12.96
Mkt Cap: $0.8B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
LENZ
LENZ Therapeutics, Inc.
$18.00
Mkt Cap: $0.5B
PROK
ProKidney Corp.
$2.37
Mkt Cap: $0.3B
RZLT
Rezolute, Inc.
$1.77
Mkt Cap: $0.2B
SPRY
ARS Pharmaceuticals, Inc.
$10.49
Mkt Cap: $1.0B
SVRA
Savara Inc.
$6.05
Mkt Cap: $1.2B
TYRA
Tyra Biosciences, Inc.
$25.51
Mkt Cap: $1.4B
Explore stocks similar to NBTX for comparison